Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Brokerages #Illumina #NASDAQILMN #Average #Recommendation #Hold #Brokerages Welcome to Americanah Blog, here is the new story we have for you today:
Illumina, Inc. (NASDAQ:ILMN – Get Rating) has been given an average rating of “Hold” by the eighteen analysts that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $257.27.
ILMN has been the topic of a number of recent analyst reports. Barclays cut their price target on shares of Illumina to $130.00 in a report on Monday, August 15th. Cowen cut their price target on shares of Illumina to $327.00 in a report on Monday, August 15th. Bank of America cut their price target on shares of Illumina from $220.00 to $200.00 in a report on Friday, August 12th. Robert W. Baird cut their price target on shares of Illumina from $306.00 to $215.00 in a report on Friday, August 12th. Finally, UBS Group cut their price target on shares of Illumina from $350.00 to $245.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th.
Illumina Stock Down 2.4 %
NASDAQ ILMN opened at $193.49 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.00 and a quick ratio of 0.82. The company’s 50 day simple moving average is $206.99 and its 200 day simple moving average is $247.75. Illumina has a 12 month low of $173.45 and a 12 month high of $436.95. The company has a market capitalization of $30.40 billion, a P/E ratio of -3,224.30, a PEG ratio of 2.23 and a beta of 1.16.
Illumina (NASDAQ:ILMN – Get Rating) last released its earnings results on Thursday, August 11th. The life sciences company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.06). Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter in the previous year, the firm earned $1.87 earnings per share. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities research analysts expect that Illumina will post 2.81 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Illumina news, SVP Alexander Aravanis sold 539 shares of the business’s stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total value of $107,800.00. Following the completion of the sale, the senior vice president now directly owns 3,346 shares of the company’s stock, valued at $669,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.
Institutional Trading of Illumina
Several large investors have recently added to or reduced their stakes in the business. Private Trust Co. NA bought a new stake in shares of Illumina during the 2nd quarter worth $25,000. Glassman Wealth Services boosted its holdings in shares of Illumina by 72.9% during the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after buying an additional 62 shares during the period. Asset Dedication LLC boosted its holdings in shares of Illumina by 75.0% during the 1st quarter. Asset Dedication LLC now owns 77 shares of the life sciences company’s stock worth $28,000 after buying an additional 33 shares during the period. Farmers & Merchants Investments Inc. bought a new stake in shares of Illumina during the 1st quarter worth $30,000. Finally, Tcwp LLC bought a new stake in shares of Illumina during the 1st quarter worth $31,000. 86.12% of the stock is owned by institutional investors.
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Receive News & Ratings for Illumina Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Illumina and related companies with MarketBeat.com’s FREE daily email newsletter.